Rita Vassena
CEO
Fecundis
Fecundis develops sperm-enhancing technologies that improve sperm functionality and increase embryo quality, based on over 20 years of research in reproductive biology. The company addresses the inefficiencies and challenges of traditional fertility treatments by providing scalable solutions that integrate into clinical workflows.
- Biotechnology
- Healthcare Technology
Updated 23 months ago
Funding
Raised to date
$2.6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional fertility treatments are often inefficient, lengthy, and can be painful for patients. These treatments face challenges in optimizing sperm functionality, which directly impacts embryo quality and the overall success of achieving pregnancy.
Solution
Fecundis develops sperm-enhancing technologies designed to improve sperm functionality and increase the success rates of infertility treatments. Their approach is rooted in reproductive biology, focusing on the molecular mechanisms at the origin of life to deliver innovative sperm solutions. These technologies are designed to seamlessly integrate into existing clinical workflows, providing scalable solutions for fertility clinics. By addressing the inefficiencies in current methods, Fecundis aims to make effective fertility treatments more accessible.
Target Audience
The primary target audience includes fertility clinics and specialists focused on improving the efficiency and success rates of their treatments.
Features
- Sperm enhancement technologies based on over 20 years of research in reproductive biology.
- Solutions designed to improve sperm functionality and increase embryo quality.
- Scalable systems that integrate into clinical workflows.
- Focus on the molecular mechanisms at the origin of life.